March 2018 Update Issued on GeoVax Labs, Inc. (GOVX-OTC)

Posted by Karen Goldfarb

March 1, 2018 at 1:51 PM

Crystal Research Associates has issued a 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Download Update

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

October 2017 Update Issued on GeoVax Labs, Inc. (GOVX-OTC)

Posted by Karen Goldfarb

October 18, 2017 at 3:50 PM

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC). The Update details GeoVax's recent news and developments, recent and anticipated clinical trial and regulatory filing milestones, and financial position. As well, the Update follows GeoVax's development, strategic relationships, and market opportunities. It is available for download below.

Download Update 

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

GeoVax Labs. (GOVX-OTC) Reports Promising Results for Lassa Fever Vaccine

Posted by Karen Goldfarb

July 11, 2017 at 4:27 PM

Promising Results Reported for GeoVax's Lassa Fever Vaccine

GeoVax announced today a significant step forward in developing its vaccine candidate for protection against Lassa hemorrhagic fever virus (LASV). Efficacy testing in a murine challenge model (using a LASV reassortant) showed a single dose of the candidate vaccine, GEO-LM01, provided 100% protection to mice infected with a lethal dose of the challenge virus.

During testing, mice were given a single-dose vaccination of GEO-LM01 into muscle tissue, then infected with 1000 Plaque Forming Unit of the challenge virus by intracranial inoculation. All vaccinated mice survived while all unvaccinated mice died within one week of infection. Vaccinated animals produced a strong T cell immune response against LASV at 10 days post vaccination. The study was conducted at the Institute of Human Virology at the University of Maryland School of Medicine in Baltimore, with a repeat of the study confirming the findings.

A member of the Arenaviridae virus family, LASV causes severe and often fatal hemorrhagic illnesses in an overlapping region with Ebola virus (EBOV). Compared to the unpredictable epidemics of filoviruses such as EBOV, LASV is endemic in West Africa with an annual incidence of over 300,000, and leading to 5,000 to 10,000 deaths.

New study data suggests that the annual number of LASV cases may actually be meaningfully higher, with 3 million infections and 67,000 deaths (making upwards of 200 million individuals at risk). There are no treatments or vaccines available today to stem LASV epidemics, even though LASV kills more people in one year than the EBOV did in the last 41 years after its first epidemic in 1976 in West Africa.

GeoVax's GEO-LM01 uses the Company's proven MVA-VLP vaccine platform, which has been shown to be safe and to induce durable antibody and T cell responses in multiple human clinical trials for GeoVax’s prophylactic HIV vaccine. Using the same platform, a single dose of GeoVax’s Ebola vaccine has been shown to protect 100% of rhesus monkeys against death.

GeoVax is also developing vaccines against Sudan virus (SUDV) and Marburg virus (MARV), two other lethal filoviruses for which no effective vaccine currently exists. In addition to developing the four individual vaccines (EBOV, LASV, SUDV, MARV), the Company’s seeks to combine the vaccines into a single tetravalent vaccine to provide broad protection for individuals at-risk for these viruses.

Lassa fever has a greater human impact than any other hemorrhagic fever virus, except for dengue fever, and despite this clear need, no vaccine has yet entered human clinical trials. GeoVax is now ready for advanced preclinical testing, which could lead to initiation of human clinical trials.

For more information on GeoVax, please refer to our Executive Informational Overview (EIO), issued on June 15, 2017. This EIO is a 80-page report detailing GeoVax's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

Download GeoVax Report 

 

*******************************************

Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.

*******************************************

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv

New Research Released on GeoVax Labs, Inc. (GOVX-OTC)

Posted by Karen Goldfarb

June 19, 2017 at 4:55 PM

An Executive Informational Overview (EIO) is now available on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC). The EIO is a 80-page report detailing GeoVax's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

Download GeoVax Report 

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

ASCO and IMS Health: Trends in the Cancer Care Market

Posted by Laura Swartz

June 2, 2016 at 3:40 PM

Tomorrow kicks off one of the year’s largest oncology conferences: the American Society of Clinical Oncology (ASCO) Annual Meeting, held this year over June 3-7 at McCormick Place in Chicago. With over 30,000 attendees and hundreds of presenting companies, the conference will undoubtedly include important clinical data announcements from the likes of Pfizer, Genentech, and others as well as give some smaller firms the opportunity to introduce novel oncology candidates. Amid the presentations and exhibitions, one topic in particular is expected to stand out: the costs of cancer care.

Read More

Topics: Crystal Research Associates, Newsworthy Events, Targeted Therapies, immunotherapy

TapImmune's New State-of-the-Art Lab Facilities and Office Space

Posted by Karen Goldfarb

January 23, 2012 at 11:19 AM

We recently received an update from TapImmune Inc. (TPIV-OTC.BB) regarding the Company's newly acquired laboratory and office space in South Lake Union (Seattle's up-and-coming biotech hub). Through a strategic sublease with the Puget Sound Blood Center Research Institute, TapImmune's scientific research team now has access to shared equipment and state-of-the-art core laboratories for DNA sequencing, Mass Spectrometry (shown below), and Fluorescent Activated Cell Sorting (FACS)—a unique opportunity for any startup company.

Read More

Topics: biotech, TapImmune, cancer vaccine, immunotherapy, Mark Reddish, Puget Sound Blood Center

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic